D. E. Shaw & Co., Inc. Karyopharm Therapeutics Inc. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 229,685 shares of KPTI stock, worth $140,107. This represents 0.0% of its overall portfolio holdings.

Number of Shares

229,685

Previous 1,047,396 78.07%

Holding current value

$140,107

Previous $869,000 82.05%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.6 - $0.99 $490,626 - $809,533	-817,711 Reduced 78.07%	229,685 $156,000
Q3 2024 Nov 14, 2024	BUY	$0.7 - $1.06 $142,298 - $215,481	203,284 Added 24.08%	1,047,396 $869,000
Q2 2024 Aug 14, 2024	SELL	$0.87 - $1.58 $103,280 - $187,566	-118,713 Reduced 12.33%	844,112 $734,000
Q1 2024 May 15, 2024	BUY	$0.72 - $1.66 $248,838 - $573,710	345,609 Added 55.99%	962,825 $1.45 Million
Q4 2023 Feb 14, 2024	SELL	$0.68 - $1.31 $3,834 - $7,387	-5,639 Reduced 0.91%	617,216 $530,000
Q3 2023 Nov 14, 2023	BUY	$1.14 - $1.81 $28,609 - $45,423	25,096 Added 4.2%	622,855 $834,000
Q2 2023 Aug 14, 2023	BUY	$1.79 - $4.59 $86,192 - $221,017	48,152 Added 8.76%	597,759 $1.07 Million
Q1 2023 May 15, 2023	BUY	$2.84 - $3.92 $686,280 - $947,260	241,648 Added 78.47%	549,607 $2.14 Million
Q4 2022 Feb 14, 2023	BUY	$2.48 - $5.93 $407,099 - $973,427	164,153 Added 114.15%	307,959 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$4.08 - $5.82 $348,048 - $496,480	85,306 Added 145.82%	143,806 $785,000
Q2 2022 Aug 15, 2022	BUY	$4.15 - $8.37 $101,206 - $204,119	24,387 Added 71.49%	58,500 $264,000
Q1 2022 May 16, 2022	SELL	$5.91 - $14.38 $838,853 - $2.04 Million	-141,938 Reduced 80.62%	34,113 $251,000
Q4 2021 Feb 14, 2022	BUY	$5.21 - $8.61 $917,225 - $1.52 Million	176,051 New	176,051 $1.13 Million
Q2 2021 Aug 16, 2021	SELL	$8.11 - $11.11 $120,555 - $165,150	-14,865 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.85 - $17.69 $13.5 Million - $24.2 Million	-1,367,268 Reduced 98.92%	14,865 $156,000
Q4 2020 Feb 16, 2021	SELL	$14.15 - $17.19 $14.2 Million - $17.3 Million	-1,005,337 Reduced 42.11%	1,382,133 $21.4 Million
Q3 2020 Nov 16, 2020	SELL	$14.14 - $19.71 $8.31 Million - $11.6 Million	-587,545 Reduced 19.75%	2,387,470 $34.9 Million
Q2 2020 Aug 14, 2020	BUY	$16.6 - $25.25 $9.48 Million - $14.4 Million	571,235 Added 23.76%	2,975,015 $56.3 Million
Q1 2020 May 15, 2020	BUY	$14.38 - $27.72 $550,308 - $1.06 Million	38,269 Added 1.62%	2,403,780 $46.2 Million
Q4 2019 Feb 14, 2020	BUY	$9.23 - $19.67 $9.09 Million - $19.4 Million	984,484 Added 71.29%	2,365,511 $45.3 Million
Q3 2019 Nov 14, 2019	BUY	$5.66 - $11.85 $3.26 Million - $6.82 Million	575,565 Added 71.46%	1,381,027 $13.3 Million
Q2 2019 Aug 14, 2019	BUY	$4.32 - $6.43 $1.55 Million - $2.31 Million	359,087 Added 80.45%	805,462 $4.82 Million
Q1 2019 May 15, 2019	BUY	$4.12 - $10.25 $1.14 Million - $2.84 Million	276,707 Added 163.09%	446,375 $2.61 Million
Q4 2018 Feb 14, 2019	SELL	$8.2 - $16.95 $439,478 - $908,435	-53,595 Reduced 24.01%	169,668 $1.59 Million
Q3 2018 Nov 14, 2018	BUY	$17.03 - $21.18 $881,319 - $1.1 Million	51,751 Added 30.17%	223,263 $3.8 Million
Q2 2018 Aug 14, 2018	SELL	$12.0 - $19.88 $48,348 - $80,096	-4,029 Reduced 2.3%	171,512 $2.91 Million
Q1 2018 May 15, 2018	BUY	$9.92 - $17.25 $1.02 Million - $1.77 Million	102,770 Added 141.22%	175,541 $2.36 Million
Q4 2017 Feb 14, 2018	BUY	$9.15 - $11.99 $111,831 - $146,541	12,222 Added 20.19%	72,771 $699,000
Q3 2017 Nov 14, 2017	BUY	$8.15 - $11.16 $493,474 - $675,726	60,549	60,549 $665,000

Others Institutions Holding KPTI

# of Institutions

Shares Held

59.6M

Call Options Held

547K

Put Options Held

67K

View Full List

About Karyopharm Therapeutics Inc.

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $48.7M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

More about KPTI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account